Literature DB >> 20685601

Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin.

Marc Pearton1, Sang-Moo Kang, Jae-Min Song, Yeu-Chun Kim, Fu-Shi Quan, Alexander Anstey, Matthew Ivory, Mark R Prausnitz, Richard W Compans, James C Birchall.   

Abstract

Virus-like particles (VLPs) have a number of features that make them attractive influenza vaccine candidates. Microneedle (MN) devices are being developed for the convenient and pain-free delivery of vaccines across the skin barrier layer. Whilst MN-based vaccines have demonstrated proof-of-concept in mice, it is vital to understand how MN targeting of VLPs to the skin epidermis affects activation and migration of Langerhans cells (LCs) in the real human skin environment. MNs coated with vaccine reproducibly penetrated freshly excised human skin, depositing 80% of the coating within 60 s of insertion. Human skin experiments showed that H1 (A/PR/8/34) and H5 (A/Viet Nam/1203/04) VLPs, delivered via MN, stimulated LCs resulting in changes in cell morphology and a reduction in cell number in epidermal sheets. LC response was significantly more pronounced in skin treated with H1 VLPs, compared with H5 VLPs. Our data provides strong evidence that MN-facilitated delivery of influenza VLP vaccines initiates a stimulatory response in LCs in human skin. The results support and validate animal data, suggesting that dendritic cells (DCs) targeted through deposition of the vaccine in skin generate immune response. The study also demonstrates the value of using human skin alongside animal studies for preclinical testing of intra-dermal (ID) vaccines. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685601      PMCID: PMC3371415          DOI: 10.1016/j.vaccine.2010.05.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

Authors:  J J Treanor; B E Wilkinson; F Masseoud; J Hu-Primmer; R Battaglia; D O'Brien; M Wolff; G Rabinovich; W Blackwelder; J M Katz
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

Review 2.  Cytokines and Langerhans cell mobilisation in mouse and man.

Authors:  C E M Griffiths; R J Dearman; M Cumberbatch; I Kimber
Journal:  Cytokine       Date:  2005-09-08       Impact factor: 3.861

3.  Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch micro-fabricated micro-needles.

Authors:  James Birchall; Sion Coulman; Marc Pearton; Chris Allender; Keith Brain; Alexander Anstey; Chris Gateley; Nicolle Wilke; Anthony Morrissey
Journal:  J Drug Target       Date:  2005-08       Impact factor: 5.121

4.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Authors:  John J Treanor; James D Campbell; Kenneth M Zangwill; Thomas Rowe; Mark Wolff
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

5.  Precise microinjection into skin using hollow microneedles.

Authors:  Ping M Wang; Megan Cornwell; James Hill; Mark R Prausnitz
Journal:  J Invest Dermatol       Date:  2006-05       Impact factor: 8.551

6.  Development of a simple and high-yielding fed-batch process for the production of influenza vaccines.

Authors:  Jamal Meghrous; Wafaa Mahmoud; Danielle Jacob; Rick Chubet; Manon Cox; Amine A Kamen
Journal:  Vaccine       Date:  2009-10-30       Impact factor: 3.641

7.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Authors:  Jiangtao Lin; Jiansan Zhang; Xiaoping Dong; Hanhua Fang; Jiangting Chen; Nan Su; Qiang Gao; Zhenshan Zhang; Yuxuan Liu; Zhihong Wang; Meng Yang; Ruihua Sun; Changgui Li; Su Lin; Mei Ji; Yan Liu; Xu Wang; John Wood; Zijian Feng; Yu Wang; Weidong Yin
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321

Review 8.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

9.  Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Control Release       Date:  2009-10-17       Impact factor: 9.776

10.  Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.

Authors:  T M Tumpey; M Renshaw; J D Clements; J M Katz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

View more
  18 in total

Review 1.  Polymeric microneedles for transdermal protein delivery.

Authors:  Yanqi Ye; Jicheng Yu; Di Wen; Anna R Kahkoska; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

Review 2.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

3.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

4.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

Review 5.  Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.

Authors:  Xueting Wang; Ning Wang; Ning Li; Yuanyuan Zhen; Ting Wang
Journal:  Hum Vaccin Immunother       Date:  2016-05-09       Impact factor: 3.452

Review 6.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

7.  Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.

Authors:  Marc Pearton; Sang-Moo Kang; Jae-Min Song; Alexander V Anstey; Matthew Ivory; Richard W Compans; James C Birchall
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

Review 8.  The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.

Authors:  Kamran Badizadegan; James L Goodson; Paul A Rota; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2020-03-17       Impact factor: 5.217

9.  Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine.

Authors:  Marc Pearton; Daniela Pirri; Sang-Moo Kang; Richard W Compans; James C Birchall
Journal:  Adv Healthc Mater       Date:  2013-04-08       Impact factor: 9.933

Review 10.  Microneedle patches for vaccination in developing countries.

Authors:  Jaya Arya; Mark R Prausnitz
Journal:  J Control Release       Date:  2015-11-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.